CPSE:NOVO BPharmaceuticals
Novo Nordisk’s Diabetes Cell Therapy Push And What It Means For Valuation
Novo Nordisk (CPSE:NOVO B) and Aspect Biosystems are moving into a new phase of their collaboration to develop advanced cellular medicines for diabetes.
The partners are working on cell-based therapies that target disease modification or potentially curative treatment options.
The program focuses on islet replacement therapy for type 1 diabetes that is designed to function without chronic immune suppression.
For readers who mostly associate Novo Nordisk with obesity treatments like Wegovy,...